Repository logo
 

Allosteric modulation of AURKA kinase activity by a small-molecule inhibitor of its protein-protein interaction with TPX2.

Published version
Peer-reviewed

Type

Article

Change log

Authors

Janeček, Matej 
Sharma, Pooja 
Emery, Amy 
Huggins, David J 

Abstract

The essential mitotic kinase Aurora A (AURKA) is controlled during cell cycle progression via two distinct mechanisms. Following activation loop autophosphorylation early in mitosis when it localizes to centrosomes, AURKA is allosterically activated on the mitotic spindle via binding to the microtubule-associated protein, TPX2. Here, we report the discovery of AurkinA, a novel chemical inhibitor of the AURKA-TPX2 interaction, which acts via an unexpected structural mechanism to inhibit AURKA activity and mitotic localization. In crystal structures, AurkinA binds to a hydrophobic pocket (the 'Y pocket') that normally accommodates a conserved Tyr-Ser-Tyr motif from TPX2, blocking the AURKA-TPX2 interaction. AurkinA binding to the Y- pocket induces structural changes in AURKA that inhibit catalytic activity in vitro and in cells, without affecting ATP binding to the active site, defining a novel mechanism of allosteric inhibition. Consistent with this mechanism, cells exposed to AurkinA mislocalise AURKA from mitotic spindle microtubules. Thus, our findings provide fresh insight into the catalytic mechanism of AURKA, and identify a key structural feature as the target for a new class of dual-mode AURKA inhibitors, with implications for the chemical biology and selective therapeutic targeting of structurally related kinases.

Description

Keywords

Aurora Kinase A, Cell Cycle Proteins, Cell Line, Tumor, HeLa Cells, Humans, Microtubule-Associated Proteins, Mitosis, Neoplasm Proteins, Nuclear Proteins, Phosphoproteins, Protein Binding, Protein Interaction Maps, Protein Kinases, Small Molecule Libraries, Spindle Apparatus

Journal Title

Sci Rep

Conference Name

Journal ISSN

2045-2322
2045-2322

Volume Title

6

Publisher

Springer Science and Business Media LLC
Sponsorship
Medical Research Council (G1001522)
Wellcome Trust (090340/Z/09/Z)
Medical Research Council (MC_UU_12022/1)
Royal Society (WM150022)
European Research Council (279337)
Engineering and Physical Sciences Research Council (EP/J016012/1)
Medical Research Council (MR/L007266/1)
Engineering and Physical Sciences Research Council (EP/K039520/1)
MRC (MC_UU_12022/8)
We are grateful for the access and support at beamlines i02, i03 and i04-1 at Diamond Light Source at Harwell, UK (proposal MX9007 and MX9537) and at beamline Proxima1 at the SOLEIL Synchrotron, Gif-sur-Yvette, France. We are grateful for access and support from the X-ray and biophysics facilities (Dept. of Biochemistry) and the screening/imaging facility (MRC Cancer Unit). M.J. was supported by a Cancer Research UK studentship held in the labs of DS and ARV, PS and MR by a Wellcome Trust Strategic Award to ARV and MH, and DJH, BH, AJN and GM by grants from the UK Medical Research Council to ARV.